Navigation Links
DelSite Signs Technology Evaluation Agreement With Global Pharmaceutical Company for GelSite(R) Polymer
Date:4/15/2008

IRVING, Texas, April 15 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (OTC Bulletin Board: CARN) today announced that its wholly-owned subsidiary, DelSite Biotechnologies, Inc., entered into a non-exclusive technology evaluation agreement with a global pharmaceutical company for the purpose of evaluating DelSite's GelSite(R) polymer-based delivery technologies.

The goal of the program is to evaluate DelSite's parenteral technologies. DelSite has agreed to provide GelSite polymer and technical information concerning the optimal solubilization and mixing conditions. Terms of the agreement were not disclosed.

Carlton E. Turner, PhD, president and CEO of Carrington Laboratories and DelSite Biotechnologies, commented, "DelSite's technologies are novel and patent-protected, and we are dedicated to developing them for a wide range of applications. This agreement represents another highlight of increased interest in DelSite's technologies within the pharmaceutical industry."

DelSite is currently developing a nasal powder H5N1 influenza vaccine based on the GelVac(TM) nasal powder platform. Advantages of the GelVac vaccine delivery platform are: room temperature stability, needle-free administration, no adjuvant requirement, no preservative requirement, no cold-chain distribution, and induction of both systemic and mucosal immunity. DelSite plans to initiate a Phase I clinical study of the flu vaccine with the GelVac platform this summer.

GelSite polymer is a novel, naturally-occurring ionic carbohydrate polymer that is capable of forming a gel upon contact with body fluids. DelSite has developed three novel delivery platforms for various applications: 1) GelVac nasal powder for nasal delivery of vaccines and therapeutics; 2) GelSure(TM) for injectable delivery of therapeutics; and 3) GPDA(TM) depot adjuvant for vaccine applications. GPDA is a unique depot adjuvant; unlike many current adjuvants, it does not stimulate immune cells
'/>"/>

SOURCE Carrington Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
2. DelSite Nasal Powder Technology Could Reduce Recently Reported Waste in Federal Vaccine Program
3. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
4. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
5. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
6. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
7. Monsanto Company Signs Share Subscription Agreement With Devgen
8. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
9. Shandong Zhouyuan Seed and Nursery Co., Ltd. Signs an Agreement with Linyi Company
10. Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge
11. Assay Designs(TM) Announces Additions to the Leadership Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... This is a professional and ... Papain industry in Global and China. The report ... definitions, applications and industry chain structure. Global market ... with a focus on history, developments, trends and ... the international and Chinese situation is also offered. ...
(Date:8/22/2014)... 2014 Today the Academy of Model Aeronautics ... Court of Appeals for the D.C. Circuit challenging the FAA’s ... the Federal Register on June 25, 2014. , The ... the text and intent of the FAA Modernization and Reform ... prohibition on any new rules or regulations regarding model aircraft ...
(Date:8/22/2014)... Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced results for the ... 2014 second quarter financial statements and MD&A have been filed on SEDAR ... , Six-months ended June 30, ( in CDN$,000 except per ... 2014 , 2013 Revenue , 2,459 , ... , 56 , 1,485 , 385 ...
(Date:8/22/2014)... Surrey have discovered how the receptors responsible for contractions ... The new study, published today in The FASEB ... turn regulates the cycle of all cells in the ... local biological clock and its control are weakened in ... bladder physiology and ageing. , While currently ...
Breaking Biology Technology:Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 2Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 3AMA Files Petition for Review of FAA’s Interpretive Rule 2Biorem Reports 2014 Second Quarter Results 2Biorem Reports 2014 Second Quarter Results 3Treatment for overactive bladder and irritable bowel syndrome advanced through pioneering research 2
... Inc. (Sparta),the maker of TrackWise(R), and the market ... that its TrackWise solution has,been chosen by Protherics ... manufacturing and marketing of specialized products for,critical care ... handling,processes. TrackWise provides organizations with a single, ...
... Oct. 24 Human Genome,Sciences, Inc. (Nasdaq: HGSI ... to discuss its financial results for the quarter ended,September ... on Thursday,November 1, 2007. (Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO ) ... management and will be,held on Thursday, November 1, 2007, ...
... Call on Thursday, October 25, 2007 at ... ... Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ), a biopharmaceutical company focused ... the treatment of life-threatening,diseases, including diabetes and cancer, today announced its ...
Cached Biology Technology:Protherics UK Ltd. Chooses TrackWise for Corrective Action and Preventive Action (CAPA) Management 2Human Genome Sciences To Sponsor Conference Call To Discuss Third Quarter 2007 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results 5Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results 6
(Date:8/22/2014)... 22, 2014 ... announced the addition of the  "Biometrics ... to their offering.       ... a technology that helps in the ... physical or behavioral features. It involves ...
(Date:8/22/2014)... , a leading source of information for businesses and ... California, Riverside in its 2014 list of "some of ... To generate the list, the company analyzed citation data ... work has had enormous impact. , The following UC ... published the greatest number of highly cited papers in ...
(Date:8/22/2014)... CA Research presented at the 29th Annual ... developed by Hera Therapeutics Inc. combats three types ... 70 percent of all cervical cancer. , When ... blocked the replication of HPV-16, HPV-18 and HPV-11 ... Thomas Broker, Ph.D., who presented the findings at ...
Breaking Biology News(10 mins):Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 2Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 35 UC Riverside scientists among world's most influential scientific minds 2
... MADISON Times are tough for wildlife living at the ... Armies are reportedly encamped in a national park and wildlife ... cattle have settled in an adjoining Ugandan park. And ... support more than 900 individuals of the emblematic African lion, ...
... Clinical Research Services (TCRS) at Scottsdale Healthcare and Mayo ... broad potential to treat solid tumors. Clinical ... TGen Clinical Research Services at Scottsdale Healthcare, a partnership ... Scottsdale-based Scottsdale Healthcare Corp., and at Mayo Clinic in ...
... AWRE ), a leading supplier of broadband technology ... the company,s operating results for the fourth quarter and fiscal ... Eastern Time. CEO Michael Tzannes and CFO Rick Moberg will ... Thomson and can be accessed on the Investor Relations page ...
Cached Biology News:Research uncovers surprising lion stronghold in war-torn central Africa 2Research uncovers surprising lion stronghold in war-torn central Africa 3TGen Clinical Research Services at Scottsdale Healthcare and Mayo Clinic study new cancer drug 2Aware Announces Q4 and FY2008 Earnings Conference Call 2
ChIP-GLAS kit for H10K-B microarray chips. Contains ChIP kit, GLAS kit, and hybridization kit. Additional reagents are required. Please see manual for details. Contains sufficient reagent for 20 reac...
...
Highly efficient electroporation solution suitable for transfection of plasmid DNA, oligonucleotides and siRNA. Compatible with all common electroporators....
Removes polysaccharide and phenolic inhibitors of PCR; yields DNA greater than 50 kb in length...
Biology Products: